Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanobiotix S A maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are distributed across 3 distinct examiners, showing that the company is engaging with multiple reviewers simultaneously. Furthermore, the portfolio spans 3 distinct art units. This distribution indicates that the company's technical applications are diverse enough to be classified into different specialized divisions within the USPTO. Practitioners can see that the company's current workload is spread across multiple administrative channels.
The busiest examiner for Nanobiotix S A is KALIHER, HANS CHRISTIAN, who is managing 1 pending office action. Since there are 3 pending office actions in total, each of the 3 distinct examiners is responsible for exactly one case. This 1 to 1 ratio between actions and examiners, along with the 3 distinct art units, suggests a varied prosecution landscape. Practitioners should be prepared to manage three different examiner styles and three sets of art unit guidelines as they move these applications forward. The data reflects a portfolio that is not dependent on any single examiner for its overall success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KALIHER, HANS CHRISTIAN | 1 | 62.9% | +27.3% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035303 | COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF CANCER | BECKHARDT, LYNDSEY MARIE | — |
| 17927372 | NANOPARTICLES, IONIZING RADIATION AND INNOVATIVE THERAPEUTIC COMBINATIONS THEREOF | GREENE, IVAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039728 | POROUS, HIGH-Z AND CARBON-FREE PARTICLES AS RADIOENHANCERS | KALIHER, HANS CHRISTIAN | — |
| 18035303 | COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF CANCER | BECKHARDT, LYNDSEY MARIE | — |
| Art Unit | Apps |
|---|---|
| 3781 | 1 |
| 1613 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18039728 | POROUS, HIGH-Z AND CARBON-FREE PARTICLES AS RADIOENHANCERS | KALIHER, HANS CHRISTIAN | 3781 | §103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18035303 | COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF CANCER | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 17927372 | NANOPARTICLES, IONIZING RADIATION AND INNOVATIVE THERAPEUTIC COMBINATIONS THEREOF | GREENE, IVAN A | 1619 | §103§112 | Final Rejection | — | Pending | Nov 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanobiotix S A has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Hans Christian Kaliher has the most, with 1 of Nanobiotix S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
